Claim OwnershipThe Biotech Startups Podcast
Subscribed: 130Played: 3,096
Subscribe
Copyrights © 2025 All Rights Reserved by Excedr
Description
The Biotech Startups Podcast by Excedr features weekly conversations with founders, scientists, and investors driving biotech innovation. Host Jon Chee dives into the challenges of building biotech startups, from pre-seed to IPO. New episodes every Monday and Thursday.
279 Episodes
Reverse
The conversation covers layoffs, company transformation, patent cliffs, biotech's feast-and-famine cycles, modified mRNA, and the effort required to scale production from tiny academic batches to grams and kilograms.
At Merck, a three-month visa detour exposed Örn to another laboratory and reinforced the value of adaptability. He then describes leaving a secure role for Transform Pharmaceuticals, building a small team and collaborative culture, developing new formulation technologies, and helping create the patents and assets that led to a Johnson & Johnson acquisition.
He describes his first research opportunity at the University of Iceland, an early industry project in Copenhagen, and the mentors who pushed him toward bioorganic chemistry. The conversation follows his move to UC Santa Barbara, his work with Tom Bruice and Alex Klibanov, and the networking connection that led to Merck.
Philip breaks down the hidden costs of traditional lab leases, from equipment maintenance and utilities to medical waste, freezer alarms, and unused square footage. He explains how flexible space can help emerging companies stay focused on milestones while preserving critical capital.
Philip Borden describes leaving Frazier Healthcare Partners for Harvard Business School, where the case method broadened his perspective beyond healthcare and investing. He explains why he returned to healthcare investing after graduation.
Comments
Download from Google Play
Download from App Store
United States